Page last updated: 2024-11-09

2,4-dithiouracil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2,4-dithiouracil: inhibitor of aspergillin biosynthesis [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1712448
CHEMBL ID3934582
SCHEMBL ID160984
SCHEMBL ID14483825
MeSH IDM0158672

Synonyms (61)

Synonym
uracil, 2,4-dithio-
nsc42031
2,4-pyrimidinedithiol
wln: t6mymyj bus dus
nsc-42031
uracil,4-dithio-
2,4-dithiouracil
usaf cb-14
dithiouracil
dithiopyrimidine
2,3h)-pyrimidinedithione
2,4-dithioxopyrimidine
2,4-dithiopyrimidine
2,4-dimercaptopyrimidine
2001-93-6
1h-pyrimidine-2,4-dithione
2,4-dimercapto pyrimidine
inchi=1/c4h4n2s2/c7-3-1-2-5-4(8)6-3/h1-2h,(h2,5,6,7,8
2,4(1h,3h)-pyrimidinedithione
pyrimidine-2,4(1h,3h)-dithione
pyrimidine-2,4-dithiol
STK361597
dithiouracil, 98%
einecs 217-894-5
nsc 42031
ai3-25475
D-8700
AKOS000526100
1193-28-8
A814174
AKOS006223236
133039-83-5
FT-0610225
AB01331643-02
SCHEMBL160984
SCHEMBL14483825
132939-82-3
4-sulfanyl-2(3h)-pyrimidinethione
AB-323/25048186
DTXSID80173827
mfcd00006042
AS-59788
1,2,3,4-tetrahydropyrimidine-2,4-dithione
132939-84-5
4(1h)-pyrimidinethione, 2-mercapto- (9ci)
2(1h)-pyrimidinethione, 6-mercapto- (9ci)
4(3h)-pyrimidinethione, 2-mercapto- (9ci)
2,4-pyrimidinedithiol (9ci)
133099-49-7
CHEMBL3934582
107686-58-8
2(1h)-pyrimidinethione, 4-mercapto- (9ci)
4(1h)-pyrimidinethione,2-mercapto-
2.4-dithiopyrimidine
D87918
NCGC00338889-01
SB55549
boc-(r)-3-amino-3-(3-bromo-phenyl)-propionicacid
4(3h)-pyrimidinethione,2-mercapto-(9ci)
2 pound not4-dimercapto
Z2311575088
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1331617Cytotoxicity against human 184B5 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity.
AID1331616Cytotoxicity against human PC3 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity.
AID1331615Cytotoxicity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay2016European journal of medicinal chemistry, Nov-10, Volume: 123Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity.
AID1331618Selectivity index, ratio of GI50 for human 184B5 cells to GI50 for human MCF7 cells2016European journal of medicinal chemistry, Nov-10, Volume: 123Chalcogen containing heterocyclic scaffolds: New hybrids with antitumoral activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's1 (9.09)18.2507
2000's2 (18.18)29.6817
2010's6 (54.55)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.57

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.57 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index5.06 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.57)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]